本帖最后由 老马 于 2013-3-13 13:43 编辑
! x8 B! R% l# c; m8 \, ^! Z( T
1 E: c6 e5 e2 W4 B健择(吉西他滨)+顺铂+阿瓦斯汀) F! F& X! |7 d4 J. O. J8 _
Gemzar +Cisplatin + Avastin, e' o/ c, D/ a% f/ Q
http://annonc.oxfordjournals.org/content/21/9/1804.full9 Y5 r9 q! A& K1 @# A
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 3 M) o6 p% Q# u- d' R8 F
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) }4 J, [0 I, Z8 v$ l; a5 H2 Z- gResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 2 c0 N8 D, O/ A2 d3 X$ P
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 258)
( r+ q9 a% A0 V5 e @6 {
华为网盘附件:
: m' v. Y: Y; M+ M7 _0 w7 Z【华为网盘】ava.JPG5 _/ ^) ]# _, t, K+ Z
|